Sensitivity of WF-OCTA in comparison to UWF-FA in diagnosing PDR and agreement between devices in detecting NVE
| UWF-FA | WF-OCTA | ||
| Diagnosis PDR, n of eyes (%) | 59 (100%) | 56 (95%)* | TPR=0.95 (95% CI 0.85 to 0.98) |
| Eyes with NVD | 16 (27.1%) | 16 (27.1%)* | |
| Eyes with NVD only | 4 (6.8%) | 5 (8.5%)* | |
| Eyes with NVE | 55 (93.2%) | 51 (86.4%)* | |
| Eyes with NVE only | 43 (72.9%) | 40 (67.8%)* | |
| Eyes with NVD and NVE | 12 (20.3%) | 11 (18.6%)* | |
| No of NVE seen on UWF-FA | 242 (100%) | 174 (71.9%)* | |
| No of NVE in quadrants | |||
| Superotemporal | 75 (30.9%) | 71 (29.3%)* | |
| Inferotemporal | 78 (32.2%) | 71 (29.3%)* | |
| Superonasal | 43 (17.7%) | 14 (5.8%)* | |
| Inferonasal | 46 (19%) | 18 (7.4%)* | |
| Median n of NVE/eye | |||
| In total (IQR) | 3 (1–7) | 2 (1–4) | κ=0.76 (95% CI 0.6 to 0.91) |
| Superotemporal | 1 (0–2) | 1 (0–2) | κ=0.98 (95% CI 0.95 to 1) |
| Inferotemporal | 1 (0–2) | 1 (0–2) | κ=0.94 (95% CI 0.88 to 1) |
| Superonasal | 0 (0–1) | 0 (0–0) | κ=0.24 (95%CI −0.04–0.5) |
| Inferonasal | 0 (0–1) | 0 (0–0) | κ=0.42 (95%CI 0.17 to 0.66) |
Distribution of NVD and NVE in eyes on UWF-FA and WF-OCTA.
*Percentage of the total number of eyes or NVEs seen on UWF-FA.
NVD, neovascularisation at the disc; NVE, neovascularisation elsewhere; OCTA, optical coherence tomography angiography; PDR, proliferative diabetic retinopathy; TPR, true positive results; UWF-FA, ultrawidefield fluorescein angiography; WF-OCTA, widefield-OCTA.